Skip to main content
. Author manuscript; available in PMC: 2015 Dec 15.
Published in final edited form as: Cancer Res. 2014 Oct 27;74(24):7217–7228. doi: 10.1158/0008-5472.CAN-14-0505

Fig. 2. Schematic of pY proteomics approach.

Fig. 2

Two DDR2-mutant lung SCC cell lines (H2286 and HCC366) were treated with dasatinib (500 μM, 3 hours) or DMSO vehicle control, followed by differential in pY peptides abundance analyzed by LC-MS/MS. Detailed methods for mass spectrometry and statistical analysis are described in Supplementary Materials and Methods.